Reuters Health News Summary

Lilly has the edge on Danish rival Novo to weather potential U.S. price cuts on its blockbuster obesity drug Zepbound, backed by stronger trial data, closer ties to the White House and its presence in the direct-to-consumer market to boost sales. Strong Sensodyne demand in US helps Haleon beat sales forecasts Consumer healthcare group Haleon's third-quarter organic revenue growth narrowly beat forecasts on Thursday as U.S. sales unexpectedly returned to growth on the back of high demand for its oral health products Sensodyne and parodontax.

Following is a summary of current health news briefs.

Indian drugmaker Cipla's global CEO Umang Vohra to step down, COO to take over

Cipla's global chief executive and managing director, Umang Vohra, will step down at the end of March after almost a decade in the top role, the Indian drugmaker said on Thursday. Achin Gupta, the firm's global chief operating officer, will take over from April 1, 2026 for five years, the company said.

Millions face food aid cliff in US government shutdown standoff

Nearly 42 million people are set to lose food aid due to the second-longest U.S. government shutdown, as Democrats and Republicans in Congress continue to blame each other for a weeks-long legislative stalemate. Neither party was showing signs of changing its position days before funding for the Supplemental Nutrition Assistance Program, also known as food stamps, is set to lapse beginning on Saturday.

Amplifon posts Q3 profit fall, confirms 2025 guidance

Italian hearing aid group Amplifon reported a 27.7% drop in its third-quarter adjusted net profit to 19.2 million euros ($22.4 million) on Wednesday. The company confirmed the 2025 guidance it had already lowered in July.

In Lilly vs Novo obesity drug battle, Trump price talks grab focus

As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are looking elsewhere: high-stakes price talks with U.S. President Donald Trump. Lilly has the edge on Danish rival Novo to weather potential U.S. price cuts on its blockbuster obesity drug Zepbound, backed by stronger trial data, closer ties to the White House and its presence in the direct-to-consumer market to boost sales.

Strong Sensodyne demand in US helps Haleon beat sales forecasts

Consumer healthcare group Haleon's third-quarter organic revenue growth narrowly beat forecasts on Thursday as U.S. sales unexpectedly returned to growth on the back of high demand for its oral health products Sensodyne and parodontax. Shares in the company rose 2.5%, helping to pare losses for the year so far to about 6%.

Eli Lilly raises forecasts on surging demand for weight-loss, diabetes drugs

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong appetite for its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro helped it breeze past third-quarter earnings estimates. Shares of the world's largest healthcare firm by market capitalization jumped over 5% in premarket trading even as investors remain wary of drug price negotiations with the Trump administration.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)